Allschwil, Switzerland, October 18, 2022
Spexis to present at BIO-Europe® 2022
Spexis AG (SIX: SPEX) today announced that the company will present and participate in one-on-one meetings at BIO-Europe®, taking place October 24-26, 2022 in Leipzig, Germany, and virtually, November 2-4, 2022.
Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline. The in-person presentation will be on Tuesday, October 25th from 13:30 to 13:45 CEST in Multi-purpose Room 4. Jeff Wager and Stephan Wehselau, COO, will both be available to participate in one-on-one meetings. To schedule a meeting with the company, please use PartneringONE®, the conference partnering system.
For further information please contact:
About Spexis
Spexis AG (SIX:SPEX) is a clinical-stage, publicly listed biopharmaceutical company. The company is focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancers. The most advanced of four clinical candidates is ColiFin®, an inhaled therapeutic for cystic fibrosis. ColiFin® is already approved and marketed in Europe and is planned to enter global pivotal Phase 3 testing in early 2023 subject to financing. Furthermore, Spexis is applying its leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With a pipeline of potentially transformative product candidates, Spexis aims to deliver substantial benefits to patients and meaningful value to society and its stakeholders. For further information, please visit: www.spexisbio.com.
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
